Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia
Open Access
- 2 September 2016
- journal article
- research article
- Published by Taylor & Francis Ltd in OncoImmunology
- Vol. 5 (10), e1226720
- https://doi.org/10.1080/2162402x.2016.1226720
Abstract
Natural killer (NK)-cell count is predictive of chronic lymphoid leukemia (CLL) disease progression and their dysfunction is well documented, but the etiology of this is currently lacking. CLL cells have been shown to over-express HLA-E, the natural ligand for NKG2A expressed on NK-cells that generates a distinct negative signal relative to direct NK-cell cytotoxicity in other disease models. Utilizing a novel anti-NKG2A monoclonal blocking antibody (mAb), monalizumab, we explored the in vitro preclinical activity of targeting the NKG2A receptor, and the NKG2A/HLA-E interaction as a mechanism of tumor evasion in CLL patients. Our work confirmed overexpression of HLA-E on CLL B-cells and demonstrated NKG2A expression on CD56+/16+ NK-cells from CLL patients. We also demonstrate that blocking NKG2A on CLL NK-cells was sufficient to restore direct cytotoxicity ability of NK-cells against HLA-E-expressing targets without impacting NK-cell mediated antibody-dependent cellular cytotoxicity. Additionally, we proved the specificity of monalizumab in blocking NKG2A through Fc-blocking mechanisms. This paper provides justification for the potential clinical utility of monalizumab in the treatment of patients with CLL.Keywords
Funding Information
- Lymphoma Research Foundation (P01-CA095426)
- National Cancer Institute
- The D. Warren Brown Foundation
This publication has 32 references indexed in Scilit:
- The clinical application of monoclonal antibodies in chronic lymphocytic leukemiaBlood, 2010
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Prognostic importance of T and NK‐cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemiaBritish Journal of Haematology, 2008
- The role of TCR stimulation and TGF‐β in controlling the expression of CD94/NKG2A receptors on CD8 T cellsEuropean Journal of Immunology, 2005
- Activating CD94:NKG2C and inhibitory CD94:NKG2A receptors are expressed by distinct subsets of committed CD8+ TCR αβ lymphocytesEuropean Journal of Immunology, 2004
- TCR Specificity Dictates CD94/NKG2A Expression by Human CTLImmunity, 2002
- Specific engagement of the CD94/NKG2-A killer inhibitory receptor by the HLA-E class Ib molecule induces SHP-1 phosphatase recruitment to tyrosine-phosphorylated NKG2-A: evidence for receptor function in heterologous transfectantsEuropean Journal of Immunology, 1998
- Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia.The Journal of Experimental Medicine, 1993
- Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemiaInternational Journal of Cancer, 1981
- On a Test of Whether one of Two Random Variables is Stochastically Larger than the OtherThe Annals of Mathematical Statistics, 1947